tetano
Editor, Senior Moderator
J Infect Dis
. 2021 Nov 19;jiab574.
doi: 10.1093/infdis/jiab574. Online ahead of print.
Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines
Donna Ambrosino[SUP] 1 [/SUP], Htay Htay Han[SUP] 2 [/SUP], Branda Hu[SUP] 2 [/SUP], Joshua Liang[SUP] 2 [/SUP], Ralf Clemens[SUP] 3 [/SUP], Marina Johnson[SUP] 4 [/SUP], George Siber[SUP] 5 [/SUP], David Goldblatt[SUP] 4 6 [/SUP]
Affiliations
Abstract
A significant correlation has been shown between the binding antibody responses against original severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and vaccine efficacy of 4 approved coronavirus disease 2019 vaccines. We therefore assessed the immune response against original SARS-CoV-2 elicited by the adjuvanted S-Trimer vaccine, SCB-2019 + CpG/alum, in the same assay and laboratory. Responses to SCB-2019 were comparable or superior for antibody to original and Alpha variant when compared with 4 approved vaccines. The comparison accurately predicted success of the recently reported efficacy trial of SCB-2019 vaccine. Immunogenicity comparisons to original strain and variants of concern should be considered as a basis for authorization of vaccines.
Keywords: COVID-19; immunogenicity; vaccine; variants of concern.
. 2021 Nov 19;jiab574.
doi: 10.1093/infdis/jiab574. Online ahead of print.
Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines
Donna Ambrosino[SUP] 1 [/SUP], Htay Htay Han[SUP] 2 [/SUP], Branda Hu[SUP] 2 [/SUP], Joshua Liang[SUP] 2 [/SUP], Ralf Clemens[SUP] 3 [/SUP], Marina Johnson[SUP] 4 [/SUP], George Siber[SUP] 5 [/SUP], David Goldblatt[SUP] 4 6 [/SUP]
Affiliations
- PMID: 34888662
- DOI: 10.1093/infdis/jiab574
Abstract
A significant correlation has been shown between the binding antibody responses against original severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and vaccine efficacy of 4 approved coronavirus disease 2019 vaccines. We therefore assessed the immune response against original SARS-CoV-2 elicited by the adjuvanted S-Trimer vaccine, SCB-2019 + CpG/alum, in the same assay and laboratory. Responses to SCB-2019 were comparable or superior for antibody to original and Alpha variant when compared with 4 approved vaccines. The comparison accurately predicted success of the recently reported efficacy trial of SCB-2019 vaccine. Immunogenicity comparisons to original strain and variants of concern should be considered as a basis for authorization of vaccines.
Keywords: COVID-19; immunogenicity; vaccine; variants of concern.